Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Targeted therapies have significantly advanced cancer treatment, especially for metastatic renal cell carcinoma (RCC).
• Four vascular endothelial growth factor (VEGF)-targeted agents, including pazopanib, are approved for metastatic RCC.
• Pazopanib's efficacy and safety were established in a phase III trial for treatment-naive or cytokine-refractory RCC.

Purpose of the Study:

• To review the efficacy and toxicity profile of pazopanib in metastatic renal cell carcinoma.
• To highlight the role of oncology nurses in managing pazopanib-related adverse events.

Main Methods:

• Phase III clinical trial comparing pazopanib to placebo in 435 patients with metastatic RCC.
• Analysis of clinical and laboratory adverse events associated with pazopanib treatment.

Main Results:

• Pazopanib showed superior progression-free survival compared to placebo.
• Common clinical adverse events included diarrhea, hypertension, nausea, anorexia, and vomiting.
• Hepatotoxicity was identified as a significant laboratory adverse event.

Conclusions:

• Pazopanib is an effective treatment option for metastatic RCC, offering improved progression-free survival.
• Understanding and managing pazopanib's toxicity profile, particularly hepatotoxicity, is crucial.
• Oncology nurses are essential in patient education and adverse event management for pazopanib therapy.